COVID-19 on Oral Health : A New Bilateral Connection for the Pandemic
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and transmission are generally known to be produced by respiratory droplets and aerosols from the oral cavity (O.C.) of infected subjects, as stated by the World Health Organization. Saliva also retains the viral particles and aids in the spread of COVID-19. Angiotensin-converting enzyme Type 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are two of the numerous factors that promote SARS-CoV-2 infection, expressed by O.C. structures, various mucosa types, and the epithelia of salivary glands. A systemic SARS-CoV-2 infection might result from viral replication in O.C. cells. On the other hand, cellular damage of different subtypes in the O.C. might be associated with various clinical signs and symptoms. Factors interfering with SARS-CoV-2 infection potential might represent fertile ground for possible local pharmacotherapeutic interventions, which may confine SARS-CoV-2 virus entry and transmission in the O.C., finally representing a way to reduce COVID-19 incidence and severity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Biomedicines - 12(2023), 1 vom: 26. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bellocchio, Luigi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 28.01.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/biomedicines12010060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367456524 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367456524 | ||
| 003 | DE-627 | ||
| 005 | 20240128232020.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biomedicines12010060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1273.xml |
| 035 | |a (DE-627)NLM367456524 | ||
| 035 | |a (NLM)38255167 | ||
| 035 | |a (PII)60 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bellocchio, Luigi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 on Oral Health |b A New Bilateral Connection for the Pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and transmission are generally known to be produced by respiratory droplets and aerosols from the oral cavity (O.C.) of infected subjects, as stated by the World Health Organization. Saliva also retains the viral particles and aids in the spread of COVID-19. Angiotensin-converting enzyme Type 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are two of the numerous factors that promote SARS-CoV-2 infection, expressed by O.C. structures, various mucosa types, and the epithelia of salivary glands. A systemic SARS-CoV-2 infection might result from viral replication in O.C. cells. On the other hand, cellular damage of different subtypes in the O.C. might be associated with various clinical signs and symptoms. Factors interfering with SARS-CoV-2 infection potential might represent fertile ground for possible local pharmacotherapeutic interventions, which may confine SARS-CoV-2 virus entry and transmission in the O.C., finally representing a way to reduce COVID-19 incidence and severity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a infection | |
| 650 | 4 | |a oral cavity (O.C.) | |
| 650 | 4 | |a respiratory syndrome | |
| 650 | 4 | |a saliva transmission | |
| 650 | 4 | |a virus signs and symptoms | |
| 700 | 1 | |a Dipalma, Gianna |e verfasserin |4 aut | |
| 700 | 1 | |a Inchingolo, Angelo Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Inchingolo, Alessio Danilo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrante, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Del Vecchio, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a Malcangi, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Palermo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Qendro, Andis |e verfasserin |4 aut | |
| 700 | 1 | |a Inchingolo, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicines |d 2013 |g 12(2023), 1 vom: 26. Dez. |w (DE-627)NLM268899797 |x 2227-9059 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |g day:26 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biomedicines12010060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 |b 26 |c 12 | ||